Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Sihuan Pharmaceutical Holdings Group ( (HK:0460) ) just unveiled an announcement.
Sihuan Pharmaceutical Holdings Group Ltd. announced the purchase of 10,000,000 shares as part of its 2022 Share Award Scheme. This transaction represents approximately 0.1089% of the total issued shares, excluding treasury shares. The purchase is part of the company’s strategic efforts to enhance its market position and align with its long-term business objectives in the pharmaceutical and medical aesthetics sectors.
The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.
More about Sihuan Pharmaceutical Holdings Group
Sihuan Pharmaceutical Holdings Group Ltd., listed on the Main Board of The Stock Exchange of Hong Kong Limited since 2010, is an international pharmaceutical and medical aesthetic company. It is driven by innovation, featuring a leading research and development technology platform, a comprehensive global product pipeline, and a robust sales system. The company focuses on advancing its medical aesthetics and biopharmaceutical businesses in China.
YTD Price Performance: 150.38%
Average Trading Volume: 87,986,735
Technical Sentiment Signal: Buy
Current Market Cap: HK$15.3B
See more data about 0460 stock on TipRanks’ Stock Analysis page.